Commonwealth Equity Services LLC Acquires 2,753 Shares of Danaher Corporation (NYSE:DHR)

Key Points

• Commonwealth Equity Services LLC increased its holdings in Danaher Corporation by 1.9%, acquiring an additional 2,753 shares, bringing its total to 144,868 shares worth approximately $29.7 million.
• Danaher reported earnings per share of $1.80 for the last quarter, exceeding analyst expectations of $1.64, with a revenue increase of 3.4% year-over-year.
• The stock has a consensus rating of "Moderate Buy", with 18 analysts recommending buy and a consensus price target of $247.61.

Commonwealth Equity Services LLC increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 144,868 shares of the conglomerate's stock after purchasing an additional 2,753 shares during the period. Commonwealth Equity Services LLC's holdings in Danaher were worth $29,698,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FAS Wealth Partners Inc. boosted its holdings in shares of Danaher by 20.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after acquiring an additional 1,639 shares during the period. MGO One Seven LLC boosted its holdings in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after acquiring an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Danaher in the first quarter valued at approximately $539,000. Horizon Financial Services LLC raised its position in shares of Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares in the last quarter. Finally, Vision Capital Management Inc. acquired a new stake in shares of Danaher in the first quarter valued at approximately $461,000. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Shares of Danaher stock opened at $199.15 on Wednesday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The stock has a market cap of $142.60 billion, a price-to-earnings ratio of 42.37, a P/E/G ratio of 2.74 and a beta of 0.73. The company's fifty day moving average is $197.95 and its 200 day moving average is $201.85.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the firm posted $1.72 earnings per share. Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. HSBC lowered their price objective on shares of Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. TD Cowen boosted their price objective on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Finally, Argus lowered their price objective on shares of Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling at Danaher

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.20% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.